Critical Contrast: Amedisys Home Health and Hospice Care (AMED) & BioScrip (BIOS)

Amedisys Home Health and Hospice Care (NASDAQ: AMED) and BioScrip (NASDAQ:BIOS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

Amedisys Home Health and Hospice Care has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, BioScrip has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Amedisys Home Health and Hospice Care and BioScrip, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedisys Home Health and Hospice Care 0 4 7 0 2.64
BioScrip 0 0 4 0 3.00

Amedisys Home Health and Hospice Care presently has a consensus price target of $62.90, indicating a potential downside of 5.33%. BioScrip has a consensus price target of $3.56, indicating a potential upside of 34.43%. Given BioScrip’s stronger consensus rating and higher probable upside, analysts clearly believe BioScrip is more favorable than Amedisys Home Health and Hospice Care.

Valuation & Earnings

This table compares Amedisys Home Health and Hospice Care and BioScrip’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amedisys Home Health and Hospice Care $1.53 billion 1.47 $30.30 million $2.21 30.06
BioScrip $817.19 million 0.41 -$64.19 million ($0.44) -6.02

Amedisys Home Health and Hospice Care has higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than Amedisys Home Health and Hospice Care, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amedisys Home Health and Hospice Care and BioScrip’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amedisys Home Health and Hospice Care 1.98% 15.14% 9.56%
BioScrip -9.45% N/A -9.35%

Institutional & Insider Ownership

95.4% of Amedisys Home Health and Hospice Care shares are owned by institutional investors. Comparatively, 84.3% of BioScrip shares are owned by institutional investors. 2.0% of Amedisys Home Health and Hospice Care shares are owned by insiders. Comparatively, 0.8% of BioScrip shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Amedisys Home Health and Hospice Care beats BioScrip on 12 of the 14 factors compared between the two stocks.

Amedisys Home Health and Hospice Care Company Profile

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

BioScrip Company Profile

BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.

Receive News & Ratings for Amedisys Home Health and Hospice Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Home Health and Hospice Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply